Literature DB >> 11707268

Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats.

Y Zou1, R Nagai, T Yamazaki.   

Abstract

Urotensin II (UII), a cyclic neuropeptide, functions not only in the central nervous system but also in non-neural systems including cardiovascular systems. In the present study we examined whether UII regulates hypertrophy in cardiomyocytes. The exposure of cultured cardiomyocytes from neonatal rats to UII dose-dependently activated extracellular signal-regulated kinases (ERKs), important molecules in the development of cardiac hypertrophy. ERK activation by UII at 100 nM peaked at 8 min after stimulation. UII markedly induced expression of specific genes encoding atrial natriuretic peptide and brain natriuretic peptide, and significantly increased amino acid incorporation into proteins. Incubation of cardiomyocytes with UII increased cell size and myofibril organisation. UII, then, might participate in cardiomyocyte hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707268     DOI: 10.1016/s0014-5793(01)03015-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  Urotensin upregulates transforming growth factor-β1 expression of asthma airway through ERK-dependent pathway.

Authors:  Wei-Xi Zhang; Ya-Feng Liang; Xiao-Ming Wang; Ying Nie; Lei Chong; Li Lin; Chun Chen; Chang-Chong Li
Journal:  Mol Cell Biochem       Date:  2012-01-21       Impact factor: 3.396

2.  Enhancement of vascular smooth muscle cell migration by urotensin II.

Authors:  Satoshi Matsusaka; Ichiro Wakabayashi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

Review 3.  Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.

Authors:  Damien Gruson; Frédéric Thys; Franck Verschuren
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

Review 4.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 5.  Is urotensin-II the new endothelin?

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

6.  Original Research: Atorvastatin prevents rat cardiomyocyte hypertrophy induced by parathyroid hormone 1-34 associated with the Ras-ERK signaling.

Authors:  Xiaogang Liu; Chunbo Zou; Chengyuan Yu; Rujuan Xie; Manshu Sui; Suhong Mu; Li Li; Shilei Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

7.  Murine and rat cavernosal responses to endothelin-1 and urotensin-II Vasoactive Peptide Symposium.

Authors:  Fernando S Carneiro; Zidonia N Carneiro; Fernanda R C Giachini; Victor V Lima; Edson Nogueira; William E Rainey; Rita C Tostes; R Clinton Webb
Journal:  J Am Soc Hypertens       Date:  2008-11

8.  The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.

Authors:  Christopher L Herold; David J Behm; Peter T Buckley; James J Foley; William E Wixted; Henry M Sarau; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

9.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

10.  Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.

Authors:  David J Behm; Christopher L Herold; Eliot H Ohlstein; Steven D Knight; Dashyant Dhanak; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.